MedTrace Logo

Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer

NCT05955196 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2024-10-09

No results posted yet for this study

Summary

Our goal is to create novel CD47-SIRPα inhibitors using small molecules to reverse TAM-mediated immune suppression and restore anti-tumor immunity in CRCs. Our program uses structure-based drug design to create selective and potent small molecule inhibitors of SIRPα-CD47 to target the tumor microenvironment with greater efficacy and lower toxicity than CD47-targeting antibodies. .

In order to study the activity of CD47-SIRPα inhibitors on the immune microenvironment of tumors, we propose to use organoids derived from biopsies of patients with colon cancer. Tumoroids preserve the patient's tumor stroma (including myeloid cells) and provide an accurate in vitro model of complex tumor immune interaction for the evaluation of immunotherapies.

Conditions

  • Cancer of the Colon

Interventions

PROCEDURE

BLOOD AND TUMOR

sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece

Sponsors & Collaborators

  • Institut Paoli-Calmettes

    lead OTHER

Principal Investigators

  • Cécile de CHAISEMARTIN, MD · Paoli Calmettes Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-09
Primary Completion
2025-01-09
Completion
2027-01-09

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05955196 on ClinicalTrials.gov